Genomics, Pharmacogenetics and Proteomics: An Integration

Abstract

Pharmacogenomics studies the influence of the genome on drug response, whereas proteomics is concerned with the range and type of proteins produced by an individual. These techniques may be used to improve drug discovery, identification and validation.

Keywords: pharmacogenomics; pharmacogenetics; proteomics; toxicogenomics; genomics

References

Drews JJ (2000) Drug discovery: a historical perspective. Science 287:1960–1964.

Maitland‐van der Zee AH, Klungel OH, Stricker BH, et al. (2002) Genetic polymorphisms: importance for response to HMG‐CoA reductase inhibitors. Atherosclerosis 163: 213–222.

Marton MJ, DeRisi JL, Bennett HA, et al. (1998) Drug target validation and identification of secondary drug target effects using DNA microarrays. Nature Medicine 4: 1293–1301.

Roses AD (2002) Genome‐based pharmacogenetics and the pharmaceutical industry. Nature Reviews Drug Discovery 1: 541–549.

Shipp MA, Ross KN, Tamayo P, et al. (2002) Diffuse large B‐cell lymphoma outcome prediction by gene expression profiling. Nature Medicine 8: 68–74.

Walker MG, Volkmuth W, Sprinzak E, et al. (1999) Prediction of gene function by genome‐scale expression analysis: prostate‐cancer associated genes. Genome Research 9: 1198–1203.

Watkins H, Rosenzweig A, Hwang DS et al. (1992) Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. New England Journal of Medicine 326: 1108–1114.

Yeoh EJ, Ross ME, Shurtleff SA, et al. (2002) Classification, subtype discovery and prediction of outcome in pediatric acute lymphoblastic leukaemia by gene expression profiling. Cancer Cell 1: 133–143.

Further Reading

Evans WE and Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487–491.

Hall IP (2002) Pharmacogenetics, pharmacogenomics and airway disease. Respiratory Research 3: 10.

Jones MB, Krutzsch H, Shu H, et al. (2002) Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2: 76–84.

Marsh S, Kwok P and McLeod HL (2002) SNP databases and pharmacogenetics: great start, but a long way to go. Human Mutation 20: 174–179.

Mehraban F and Tomlinson JE (2001) Application of industrial scale genomics to discovery of therapeutic targets in heart failure. European Journal of Heart Failure 3: 641–650.

Onyango P (2002) Genomics and cancer. Current Opinion in Oncology 14: 79–85.

Pennie WD, Woodyatt NJ, Aldridge TC and Orphanides G (2001) Application of genomics to the definition of the molecular basis for toxicity. Toxicology Letters 120: 353–358.

Ravussin E and Bouchard C (2000) Human genomics and obesity: finding appropriate drug targets. European Journal of Pharmacology 410: 131–145.

Shi MM, Bleavins MR and de la Iglesia FA (2001) Pharmacogenetic application in drug development and clinical trials. Drug Metabolism and Disposition 29: 591–595.

Weinshilboum R (2003) Inheritance and drug response. New England Journal of Medicine 348: 529–537.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Wilkins, Martin R, Shiga, Tsuyoshi, Hughes, Robert, and Town, Margaret(Jan 2006) Genomics, Pharmacogenetics and Proteomics: An Integration. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1038/npg.els.0006189]